Alzheimer’s Disease Neurofibrillary Pathophysiology: PTPRD- and Flavonol-Modified Mechanisms, Prevention and Therapeutics

A variety of evidence now supports two interrelated hypotheses concerning Alzheimer’s disease (AD) neurofibrillary pathology (NFT), its prevention and treatment. The first hypothesis: the receptor type protein tyrosine phosphatase D (PTPRD) plays a key role in AD NFT pathogenesis by modulating activities of neuronal glycogen synthase kinase 3s (GSK3s) in hyperphosphorylating tau. The second hypothesis: positive allosteric modulation of PTPRD’s downregulation of GSK3s by flavonols and improved flavonol analogs provides a novel path to prevention and treatment of AD. We review the convergence of evidence from human, mouse, in vitro and in silico studies that enhances the likely translational relevance of these hypotheses.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-09-29
DOI
https://doi.org/10.3390/biomedicines14102210
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Alzheimer’s Disease Neurofibrillary Pathophysiology: PTPRD- and Flavonol-Modified Mechanisms, Prevention and Therapeutics

Kevin P. Schultz, Joungil Choi, George R. Uhl, Hadley Dowell et al.
Biomedicines
Alzheimer's disease research and treatments
article

Alzheimer’s Disease Neurofibrillary Pathophysiology: PTPRD- and Flavonol-Modified Mechanisms, Prevention and Therapeutics

Kevin P. Schultz, Joungil Choi, George R. Uhl, Hadley Dowell, Ian Henderson, Balaji Kannan, Emily Hess, Hanna Rogers, Darcy McFarland, Sean Nolan
article en

Abstract

A variety of evidence now supports two interrelated hypotheses concerning Alzheimer’s disease (AD) neurofibrillary pathology (NFT), its prevention and treatment. The first hypothesis: the receptor type protein tyrosine phosphatase D (PTPRD) plays a key role in AD NFT pathogenesis by modulating activities of neuronal glycogen synthase kinase 3s (GSK3s) in hyperphosphorylating tau. The second hypothesis: positive allosteric modulation of PTPRD’s downregulation of GSK3s by flavonols and improved flavonol analogs provides a novel path to prevention and treatment of AD. We review the convergence of evidence from human, mouse, in vitro and in silico studies that enhances the likely translational relevance of these hypotheses.

BiomedicinesVol. 14(10)
University of Maryland, Baltimore (US), University of New Mexico (US), VA Maryland Health Care System (US), Goucher College (US)
Good health and well-being
Openalex Percentile: Top 12%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Alzheimer’s Disease Neurofibrillary Pathophysiology: PTPRD- and Flavonol-Modified Mechanisms, Prevention and Therapeutics — Kevin P. Schultz, Joungil Choi, et al. · Biomedicines (2026) | TGRS Research Map | TGRS